The discovery of penicillin a hundred years ago was a major medical breakthrough that initiated the development of antibiotics. However, their intensive or unsuitable use led to the emergence of pathogens resistant or multi-resistant to all classes of antibiotics. This dramatic situation is leading scientists to search for (i) new molecules whose structure and mode of action differ and (ii) new targets in order to prevent resistance. In the BioCat team, we are concerned about this problem of bacterial multidrug resistance (MDR) and several projects emerged in this context: (i) the NAD biosynthesis in some pathogens (H. pylori, M. leprae) as a promising target pathway; (ii) the Fe-S biogenesis in M. tuberculosis as a good target to fight Tuberculosis; (iii) the methanogenesis pathway that needs to be inhibited to fight climate warming; (iv) a project focusing on ribosomally synthesized and post-translationally modified peptides (RiPPs) as new molecules against resistant and MDR strains and (v) a project aiming at inhibiting FUR virulence through peptides vectorisation.



​